CSIMarket
 
Longeveron Inc   (NASDAQ: LGVN)
Other Ticker:  
 
 
Price: $1.4600 $-0.02 -1.351%
Day's High: $1.48 Week Perf: -5.81 %
Day's Low: $ 1.43 30 Day Perf: -18.44 %
Volume (M): 98 52 Wk High: $ 6.40
Volume (M$): $ 143 52 Wk Avg: $2.40
Open: $1.48 52 Wk Low: $0.77



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 13
 Employees 25
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 1

Longeveron Inc
Longeveron Inc is a biotechnology company that specializes in the development of innovative cellular therapies aimed at improving the health and longevity of individuals. The company focuses on researching and developing regenerative medicine products derived from adult stem cells. Their therapies target various medical conditions such as Alzheimer's disease, aging frailty, metabolic syndrome, and other age-related diseases. Longeveron Inc aims to harness the regenerative potential of stem cells to provide new treatment options that enhance overall health and extend human lifespan.


   Company Address: 1951 NW 7th Avenue Miami 33136 FL
   Company Phone Number: 909-0840   Stock Exchange / Ticker: NASDAQ LGVN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARDX   -0.72%    
CAPR   -5.93%    
HOOK   -11.52%    
MRUS   -3.72%    
ORGO        0.28% 
TSVT   -14.96%    
• View Complete Report
   



Management Changes

Longeveron Appoints Devin Blass as CTO, Prepares for BLA Filing Amid Financial Challenges and Focus on Alzheimer?s Therapy,

Published Mon, Nov 11 2024 2:05 PM UTC

In a significant move aimed at bolstering its strategic framework and advancing its scientific endeavors, Longeveron Inc., a pioneering entity in cellular therapies, has announced the appointment of Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing and Controls (CMC), effective December 2, 2024. This transition comes at a piv...

Clinical Study

A Convergence of Scientific Ingenuity Longeveron?s Participation in the Esteemed Alliance for Regenerative Medicine...

Published Thu, Sep 26 2024 1:05 PM UTC

In the year of our Lord two thousand and twenty-three, within the hallowed halls of scientific discourse, the venerable firm, Longeveron, prepares to grace the illustrious Alliance for Regenerative Medicine?s distinguished convening, known as the Cell & Gene Meeting on the Mesa. This momentous event, a veritable symposium of the foremost minds in the realm of regenerative th...

Clinical Study

Navigating the Regulatory Landscape Longeverons Lomecel-B and the Future of Rare Pediatric Cardiac Disease Treatment

Published Tue, Sep 3 2024 1:01 PM UTC

The intersection of healthcare innovation and regulatory frameworks is a pivotal area in the pharmaceutical sciences, especially for diseases that are rare and challenging to treat, such as Hyoplastic Left Heart Syndrome (HLHS). Longeveron, a clinical-stage biotechnology company, stands at the forefront of this narrative with its investigational product, Lomecel-B. Recent a...

Stocks on the Move

Navigating the Emotional Landscape Longeveron Inc.s Rollercoaster Journey Through FDA Endorsements and Market Realities,

Published Thu, Aug 15 2024 8:48 AM UTC

Abstract Longeveron Inc. (NASDAQ: LGVN), a Miami-based clinical-stage biotechnology firm, has experienced significant fluctuations in its stock price over the past several weeks. Following the recent announcement of a $9 million registered direct offering and subsequent FDA Fast Track designation for its lead product Lomecel-B in the treatment of mild Alzheimer?s disease, in...

Clinical Study

Innovative Cellular Therapy Shows Promise in Mild Alzheimers Disease Findings from the CLEAR MIND Phase 2a Trial

Published Sun, Jul 28 2024 8:51 PM UTC

In recent years, the pursuit of effective treatments for Alzheimer?s disease has prompted researchers to explore innovative therapeutic strategies, including cellular-based therapies. Longeveron, a biotechnology company focused on developing cellular therapies, recently presented findings from their CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer s disease ...







Longeveron Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com